PHAT
Phathom Pharmaceuticals Inc
Halal Rating :
Last Price
$6.97
Last updated:
Market Cap
-
7D Change
5.29%
1 Year Change
-11.21%
Company Overview
Industries
Exchange
Next Earnings Date
Phathom Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's lead product candidate is vonoprazan, a novel potassium-competitive acid blocker (P-CAB) for the treatment of acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $16.35m | $105.63m | - | $18.48m | 0.00% | 17.50% |
| June 30, 2024 | $7.32m | $102.39m | - | $17.76m | 0.00% | 17.35% |
| March 31, 2024 | $1.91m | $89.03m | - | $17.17m | 0.00% | 19.28% |
Company Impact
Help us evaluate Phathom Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.